

{
   "uid": "2.25.154702496015696619913702792331772512838",
   "name": "VASARI LGG 4.2",
   "authors": "Justin Kirby",
   "version": "4.2",
   "creationDate": "2013-08-26",
   "description": "Baseline Glioma MR tumor assessment to include potential features for low grade glioma (LGG).",
   "schemaLocation": "gme://caCORE.caCORE/3.2/edu.northwestern.radiology.AIMTemplate AIMTemplate_v2rv13.xsd",
   "Template": {
      "templateType": "Image",
      "uid": "2.25.157319026500100654541531571593125855847",
      "name": "VASARI 4.2 for ePAD",
      "authors": "Justin Kirby",
      "version": "4.2",
      "creationDate": "2013-08-26",
      "description": "Baseline Glioma MR tumor assessment to include potential features for low grade glioma (LGG).",
      "modality": "MR",
      "codeMeaning": "VASARI",
      "codeValue": "99PRI_TC_0A23",
      "codingSchemeVersion": "1.0",
      "codingSchemeDesignator": "99PRI_TempCode",
      "Component": [
         {
            "label": "Tumor",
            "itemNumber": "0",
            "authors": "Justin Kirby",
            "explanatoryText": "",
            "minCardinality": "1",
            "maxCardinality": "1",
            "shouldDisplay": "false",
            "groupLabel": "",
            "id": "2.25.150776022310855362644669615058239870060",
            "ImagingObservation": {
               "annotatorConfidence": "false",
               "ImagingObservationCharacteristic": [
                  {
                     "label": "F0 - Image QA",
                     "itemNumber": "0",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Quality assurance pre-check. Inventory of required image series including FLAIR/T2 and pre/post contrast T1WI.",
                     "minCardinality": "0",
                     "maxCardinality": "4",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.41762360117754513539982904068277651900",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "01",
                           "codeMeaning": "Post biopsy (requires adjudication)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "02",
                           "codeMeaning": "Post-op study (disqualified)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "noMoreQuestions": "true"
                        },
                        {
                           "codeValue": "03",
                           "codeMeaning": "No Contrast Injected (disqualified)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "noMoreQuestions": "true"
                        },
                        {
                           "codeValue": "04",
                           "codeMeaning": "No T2 AND no T2 FLAIR images (disqualified)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "noMoreQuestions": "true"
                        }
                     ]
                  },
                  {
                     "label": "F1 - Anatomic Center",
                     "itemNumber": "1",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Location of tumor geographic center (using either CET or nCET); If multiple lesions/tumor, the location of the single largest component of the tumor.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.176207087037859470836228378719456039233",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID6440",
                           "codeMeaning": "frontal lobe",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6476",
                           "codeMeaning": "temporal lobe",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6493",
                           "codeMeaning": "parietal lobe",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6502",
                           "codeMeaning": "occipital lobe",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6472",
                           "codeMeaning": "insula",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6677",
                           "codeMeaning": "brainstem",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6815",
                           "codeMeaning": "cerebellum",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6549",
                           "codeMeaning": "lentiform nucleus",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6545",
                           "codeMeaning": "caudate nucleus",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6578",
                           "codeMeaning": "thalamus",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6915",
                           "codeMeaning": "corpus callosum",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "05",
                           "codeMeaning": "Posterior temporal/inferior parietal/anterior lateral occipital region",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F2 - Side of Tumor Center",
                     "itemNumber": "2",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Side of tumor center irrespective of whether the tumor crosses into the contralateral hemisphere.  If multiple lesions/tumor, the location of the single largest component of the tumor. If the tumor crosses midline, select the side of greater tumor volume.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.232717518690915622770043036906281482401",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "G-A100",
                           "codeMeaning": "Right",
                           "codingSchemeDesignator": "SRT",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "G-A102",
                           "codeMeaning": "Center/Bilateral",
                           "codingSchemeDesignator": "SRT",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        },
                        {
                           "codeValue": "G-A101",
                           "codeMeaning": "Left",
                           "codingSchemeDesignator": "SRT",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  },
                  {
                     "label": "F6 - Relative Proportion of nCET",
                     "itemNumber": "3",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Cardinal feature assessment. Assuming that the entire abnormality (“lesion”) may be comprised of: (1) an enhancing component (CET), (2) a non-enhancing component (nCET), (3) a necrotic component and (4) a edema component;  when assessing relative proportions of the these four features through the entire volume, provide in rank order where nonenhancing tumor (nCET and not edema) would occur in relative proportion to the other cardinal features (where a response of 1 indicates that this feature comprises the majority of the tumor footprint and 4 is the minority). If the feature is not present with reasonable certainty then select None.    Non-enhancing tumor (nCET) is defined as regions of non-enhancing T2W intermediate hyperintensity (less than the intensity of cerebrospinal fluid or vasogenic edema, with corresponding T1W hypointensity) that are associated with mass effect and architectural distortion, including blurring of the gray-white interface. (This may be difficult to discern from vasogenic edema).",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.44354855842637669359741888365294257264",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID5996",
                           "codeMeaning": "1",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID5998",
                           "codeMeaning": "2",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6000",
                           "codeMeaning": "3",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6002",
                           "codeMeaning": "4",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28454",
                           "codeMeaning": "none",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F14 - Relative Proportion of Edema",
                     "itemNumber": "4",
                     "authors": "Default User",
                     "explanatoryText": "Cardinal feature assessment. Assuming that the entire abnormality (“lesion”) may be comprised of: (1) an enhancing component, (2) a non-enhancing component, (3) a necrotic component and (4) a edema component; when assessing relative proportions of the these four features through the entire lesion volume, provide in rank order where vasogenic edema would occur in relative proportion to the other cardinal features (where a response of 1 indicates that this feature comprises the majority of the tissue footprint). If the feature is not present with reasonable certainty then select None.     Edema should be greater in signal than nCET and somewhat lower in signal than CSF on T2W or T2W FLAIR. Pseudopods are characteristic of edema extending up to the subcortical white matter but not infiltrating gray matter/cortex.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.39965913395033787783105725303724230275",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID5996",
                           "codeMeaning": "1",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID5998",
                           "codeMeaning": "2",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6000",
                           "codeMeaning": "3",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6002",
                           "codeMeaning": "4",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28454",
                           "codeMeaning": "none",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F5 - Relative Proportion of Enhancing Tissue",
                     "itemNumber": "5",
                     "authors": "Default User",
                     "explanatoryText": "Cardinal feature assessment. Assuming that the entire abnormality (“lesion”) may be comprised of: (1) an enhancing component, (2) a non-enhancing component, (3) a necrotic component and (4) a edema component; when assessing relative proportions of the these four features through the entire lesion volume, provide in rank order where enhancing tumor would occur in relative proportion to the other cardinal features (where a response of 1 indicates that this feature comprises the majority of the lesion footprint). If the feature is not present with reasonable certainty then select None.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.78683761429594522536391487074591144293",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID5996",
                           "codeMeaning": "1",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID5998",
                           "codeMeaning": "2",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6000",
                           "codeMeaning": "3",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6002",
                           "codeMeaning": "4",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28454",
                           "codeMeaning": "none",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F7 - Relative Proportion of Necrotic Tissue",
                     "itemNumber": "6",
                     "authors": "Default User",
                     "explanatoryText": "Cardinal feature assessment. Assuming that the entire abnormality (“lesion”) may be comprised of: (1) an enhancing component, (2) a non-enhancing component, (3) a necrotic component and (4) a edema component; when assessing relative proportions of the these four features through the entire tissue volume, provide in rank order where necrosis would occur in relative proportion to the other cardinal features (where a response of 1 indicates that this feature comprises the majority of the tissue footprint). If the feature is not present with reasonable certainty then select None.    Necrosis is defined as a region within the tumor that does not enhance, is intermediate to hyperintense on T2WI and hypointense on T1W images, and has an irregular border).",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.44789955006717697624977915911861534414",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID5996",
                           "codeMeaning": "1",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID5998",
                           "codeMeaning": "2",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6000",
                           "codeMeaning": "3",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6002",
                           "codeMeaning": "4",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28454",
                           "codeMeaning": "none",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F22 - T2/FLAIR envelope  Crosses Midline",
                     "itemNumber": "7",
                     "authors": "Justin Kirby",
                     "explanatoryText": "T2/FLAIR envelope crosses midline is defined by any T2/FLAIR signal of the lesion envelope that extends into the contralateral hemisphere through white matter commissures usually expected at the midline (exclusive of herniated ipsilateral tissue).  Unless otherwise specified, if there are multiple lesions in the same patient, the feature applies to the most aggressive-appearing lesion.  If all lesions appear equally aggressive, the feature applies to the larger/largest lesion.  Aggressiveness should be considered as the suspected area of highest-grade tumor (the area that would ideally be biopsied for accurate tumor grading, assuming injury to functional areas is not considered).",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.122361456361381677712105130790092686431",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID28475",
                           "codeMeaning": "no",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        },
                        {
                           "codeValue": "RID28474",
                           "codeMeaning": "yes",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  },
                  {
                     "label": "F13 - Definition of the non-enhancing margin (e.g. Grade III)",
                     "itemNumber": "8",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Using the T2WI preferably (or T2 FLAIR if no T2WI are available) while comparing to post-contrast T1-weighted images, assess the definition of the boundary between the T2 envelope and normal parenchyma or CET.  Evaluate the proportion of the entire lesion boundary that is well-defined or poorly-defined. If most of the outside margin of the lesion is well-defined (i.e. sharply marginated) and smooth (geographic), versus if the margin is poorly-defined (fluffy or indistinct).  Unless otherwise specified, if there are multiple lesions in the same patient, the feature applies to the most aggressive-appearing lesion.  If all lesions appear equally aggressive, the feature applies to the larger/largest lesion.  Aggressiveness should be considered as the suspected area of highest-grade tumor (the area that would ideally be biopsied for accurate tumor grading, assuming injury to functional areas is not considered).",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.106559230524219651563830084341678542715",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "11",
                           "codeMeaning": "Completely well-defined (100%)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "12",
                           "codeMeaning": "Mostly well-defined (>two thirds)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "13",
                           "codeMeaning": "Mixed (@ 50-50)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "14",
                           "codeMeaning": "Mostly poorly-defined (> two thirds)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "15",
                           "codeMeaning": "Completely ill-defined (100%)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F4 - Enhancement Quality",
                     "itemNumber": "9",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Qualitative degree of contrast enhancement is defined as havingall or portions of the tumor that demonstrate significantly higher signal on the postcontrast T1W images compared to precontrast T1W images.  Mild = when barely discernible but unequivocal degree of enhancement is present relative to pre-contrast images. Marked = obvious tissue enhancement.    (If it does not appear that contrast was administered, the case should have been disqualified in feature F0.)   Unless otherwise specified, if there are multiple lesions in the same patient, the feature applies to the most aggressive-appearing lesion.  If all lesions appear equally aggressive, the feature applies to the larger/largest lesion.  Aggressiveness should be considered as the suspected area of highest-grade tumor (the area that would ideally be biopsied for accurate tumor grading, assuming injury to functional areas is not considered).",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.183360277954448684227779109363922125763",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "16",
                           "codeMeaning": "No Contrast Enhancement",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true",
                           "nextId": "2.25.26682643709598967654598600492845350904"
                        },
                        {
                           "codeValue": "RID5671",
                           "codeMeaning": "Mild",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID34299",
                           "codeMeaning": "Marked",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  },
                  {
                     "label": "F11 - Thickness of Enhancing Margin",
                     "itemNumber": "10",
                     "authors": "Justin Kirby",
                     "explanatoryText": "If most of the enhancing rim is thin, regular, and measures < 3mm in thickness and has homogenous enhancement the grade is minimal. If most of the rim demonstrates nodular and/or thick enhancement measuring 3mm or more, the grade is thick/nodular. If there is only solid enhancement and no rim, the grade is solid.  (If it does not appear that contrast was administered, the case should have been disqualified in feature F0.)   Unless otherwise specified, if there are multiple lesions in the same patient, the feature applies to the most aggressive-appearing lesion.  If all lesions appear equally aggressive, the feature applies to the larger/largest lesion.  Aggressiveness should be considered as the suspected area of highest-grade tumor (the area that would ideally be biopsied for accurate tumor grading, assuming injury to functional areas is not considered).",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.107001996721789954075761163370350439566",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "16",
                           "codeMeaning": "No Contrast Enhancement",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        },
                        {
                           "codeValue": "RID5670",
                           "codeMeaning": "Minimal",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28672",
                           "codeMeaning": "Thick/nodular (=> 3mm)",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID5741",
                           "codeMeaning": "Solid",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  },
                  {
                     "label": "F12 - Definition of the Enhancing Margin",
                     "itemNumber": "11",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Assess if most of the outside margin of the enhancement is well defined (i.e. sharply marginated) or poorly-defined (fluffy or indistinct). Are you able to easily trace the margin of enhancement? Assess the proportion of the enhancing rim that is well-defined versus poorly defined and respond accordingly. If both thicker slices and thinner slices of post-contrast images are available, use the thinner slices.  Unless otherwise specified, if there are multiple lesions in the same patient, the feature applies to the most aggressive-appearing lesion.  If all lesions appear equally aggressive, the feature applies to the larger/largest lesion.  Aggressiveness should be considered as the suspected area of highest-grade tumor (the area that would ideally be biopsied for accurate tumor grading, assuming injury to functional areas is not considered).",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.96907076645142593218277802103517844235",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "16",
                           "codeMeaning": "No Contrast Enhancement",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        },
                        {
                           "codeValue": "17",
                           "codeMeaning": "Completely well-defined (100%)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "18",
                           "codeMeaning": "Mostly well-defined (> two thirds)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "19",
                           "codeMeaning": "Mixed (@ 50-50)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "20",
                           "codeMeaning": "Mostly poorly-defined (> two thirds)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "21",
                           "codeMeaning": "Completely ill-defined (100%)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  },
                  {
                     "label": "F23 - Enhancing tumor Crosses Midline",
                     "itemNumber": "12",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Enhancing tissue crosses midline is defined by any CET that extends into the contralateral hemisphere through white matter commissures usually expected at the midline (exclusive of herniated ipsilateral tissue).",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.200903160931839215990776770240425301421",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "16",
                           "codeMeaning": "No Contrast Enhancement",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        },
                        {
                           "codeValue": "RID28475",
                           "codeMeaning": "no",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28474",
                           "codeMeaning": "yes",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  },
                  {
                     "label": "F24 - Satellites",
                     "itemNumber": "13",
                     "authors": "Justin Kirby",
                     "explanatoryText": "A satellite lesion is defined by one or more areas of CET within the region of T2/FLAIR signal abnormality surrounding the dominant lesion but not contiguous in any part with the major enhancing tumor mass.  This is in distinction from a multifocal lesion.  No enhancing tumor rather than absent should be selected if there is no enhancing tumor.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.250254746072336007090635407167613459133",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID28473",
                           "codeMeaning": "absent",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        },
                        {
                           "codeValue": "RID28472",
                           "codeMeaning": "present",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6056",
                           "codeMeaning": "No enhancing tumor",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  },
                  {
                     "label": "F31 - Heterogeneity",
                     "itemNumber": "14",
                     "authors": "Justin Kirby",
                     "explanatoryText": "When assessing the complexity of the internal architecture of the tumor on FLAIR or T2WI overall grade the uniformity of the tumor matrix (exclusive of what appears to clearly be edema and exclusive of cysts/necrosis).  Select completely homogeneous when the tumor matrix is completely uniform in consistency; mostly homogeneous when more than 2/3 of the tumor matrix is uniform; mixed when about half of the tumor is homogeneous; mostly heterogeneous when more than 2/3 of the tumor volume is non-uniform; completely heterogeneous when all of the tumor matrix is non-uniform.  FLAIR should be used primarily.  T2WI can be used when FLAIR images are not included.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.26682643709598967654598600492845350904",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "22",
                           "codeMeaning": "Completely homogeneous (100%)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "23",
                           "codeMeaning": "Mostly homogeneous (> two thirds)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "24",
                           "codeMeaning": "Mixed (@ 50-50)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "25",
                           "codeMeaning": "Mostly heterogeneous (> two thirds)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "26",
                           "codeMeaning": "Completely heterogeneous (100%)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "27",
                           "codeMeaning": "Indeterminate",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F32 - Shape",
                     "itemNumber": "15",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Shape is defined as the overall contour of the abnormal tissue that you would characterize as a tumor boundary. Which descriptor best defines the shape of the entire mass: round, ovoid, lobulated or irregular.  Consider the overall boundaries of the CET primarily.  If there is no CET, then consider the shape of the nCET exclusive of edema.  If neither seem to apply, select none apply.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.89697414760266572521897673992093043420",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID29173",
                           "codeMeaning": "Round/Circular/Spherical",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID29223",
                           "codeMeaning": "Ovoid",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID29174",
                           "codeMeaning": "Lobulated",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID29215",
                           "codeMeaning": "Irregular",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28454",
                           "codeMeaning": "None Apply",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F8 - Cyst(s)",
                     "itemNumber": "16",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Cysts are well defined, rounded, often eccentric regions of very bright T2W signal and low T1W signal essentially matching CSF signal intensity, with very thin, regular, smooth, nonenhancing or regularly enhancing walls, possibly with thin, regular, internal septations.  Differentiate from a necrotic enhancing tumor cavity with thick irregular walls and complex internal fluid.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.36798094312158401784401963599403502954",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID28473",
                           "codeMeaning": "absent",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        },
                        {
                           "codeValue": "RID28472",
                           "codeMeaning": "present",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  },
                  {
                     "label": "F9 - Multiple lesions",
                     "itemNumber": "17",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Multiple separate lesions without continuity of the T2/FLAIR envelope.  Gliomatosis refers to generalized neoplastic transformation of the white matter of at least 3 lobes.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.122848646282931218782733302616118513507",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "37",
                           "codeMeaning": "Multiple lesions in the same hemisphere",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "38",
                           "codeMeaning": "Multiple lesions in different hemispheres or above and below the tentorium",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "28",
                           "codeMeaning": "Gliomatosis Cerebri",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "39",
                           "codeMeaning": "Solitary Lesion",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F10 - T1/FLAIR Ratio",
                     "itemNumber": "18",
                     "authors": "Justin Kirby",
                     "explanatoryText": "T1/FLAIR ratio is a gross comparison in the overall lesion size between pre-contrast T1 and FLAIR (in the same plane).  Select T1~FLAIR when pre-contrast T1 abnormality (exclusive of signal intensity) approximates size of FLAIR abnormality; Select T1<FLAIR when the size of T1 abnormality is moderately smaller than the surrounding FLAIR envelope;  or select T1<<FLAIR when the size of the pre-contrast T1 abnormality is much smaller than size of FLAIR abnormality. (If no FLAIR images were provided select No FLAIR images).",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.192557928867048244599609691480357185195",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "29",
                           "codeMeaning": "T1 ~ FLAIR",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "30",
                           "codeMeaning": "T1 < FLAIR",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "31",
                           "codeMeaning": "T1 << FLAIR",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28454",
                           "codeMeaning": "No FLAIR",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F16 - Hemorrhage",
                     "itemNumber": "19",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Intrinsic hemorrhage anywhere in the tumor matrix. Any intrinsic foci of low signal on T2WI (or gradient echo) or high signal on T1WI.  Proportion is not a discriminating factor. Select cannot determine if findings are indistinct or may actually represent mineral instead of hemorrhage.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.244477578050994548304476816368493665785",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID28475",
                           "codeMeaning": "no",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28474",
                           "codeMeaning": "yes",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "27",
                           "codeMeaning": "Indeterminate",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F17 - Diffusion",
                     "itemNumber": "20",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Proportion of any of the entire lesion (total T2/FLAIR envelope, which includes edema, nCET, CET and necrosis) demonstrating ADC below or same as the ADC of normal-appearing white matter. The remainder of the abnormality is assumed to demonstrate increased ADC relative to normal-appearing whiate matter. (Based on ADC map only). Select equivocal when findings are equivocal.   (Select no ADC images if ADC images were not provided)",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.195794272294395372341575500719340322354",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "C48660",
                           "codeMeaning": "No ADC images",
                           "codingSchemeDesignator": "NCIt",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        },
                        {
                           "codeValue": "32",
                           "codeMeaning": "> 2/3",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "33",
                           "codeMeaning": "1/3 - 2/3",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "34",
                           "codeMeaning": "< 1/3",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "35",
                           "codeMeaning": "Minimal (<5%)",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28454",
                           "codeMeaning": "None",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "36",
                           "codeMeaning": "Equivocal",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  },
                  {
                     "label": "F20 - Cortical involvement",
                     "itemNumber": "21",
                     "authors": "Justin Kirby",
                     "explanatoryText": "For non-enhancing, use T2 FLAIR preferably (or T2WI if T2 FLAIR are not available). Cortical involvement is defined by non-enhancing or enhancing tumor that extends into the cortical mantle, or if the cortex is no longer distinguishable relative to tumor.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.167777512011251856249859492928947268475",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "40",
                           "codeMeaning": "Enhancing only",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "41",
                           "codeMeaning": "Non-enhancing only",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "42",
                           "codeMeaning": "Both enhanging and non-enhancing",
                           "codingSchemeDesignator": "99VASARI",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28473",
                           "codeMeaning": "None",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F18 - Leptomeningeal reaction",
                     "itemNumber": "22",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Leptomeningeal reaction is defined by enhancement of the overlying pia/arachnoid in continuity with enhancing or non-enhancing tumor or sulcal hyperintensity on T2 FLAIR. This should be selected to capture reactive leptomeninges and/or invaded leptomeninges.  If no enhancement of the overlying pia/arachnoid in contiguity with the lesion AND no T2 FLAIR images are available, select No T2 FLAIR; do not score using standard T2W. If there IS enhancement, but no T2 FLAIR, select “present.”",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.108391085698639462771043090863419726717",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID28473",
                           "codeMeaning": "absent",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID28472",
                           "codeMeaning": "present",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "C48660",
                           "codeMeaning": "No T2 FLAIR",
                           "codingSchemeDesignator": "NCIt",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        }
                     ]
                  },
                  {
                     "label": "F19 - Ependymal contact",
                     "itemNumber": "23",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Ependymal contact is defined by any portion of the lesion abutting any adjacent ependymal surface.  This this includes any portion of the T2 envelope or any portion of CET.",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.139645378053990855460137174034728343184",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID28473",
                           "codeMeaning": "absent",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        },
                        {
                           "codeValue": "RID28472",
                           "codeMeaning": "present",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  },
                  {
                     "label": "F21 - Deep WM Invasion",
                     "itemNumber": "24",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Deep white matter invasion is defined by enhancing or nCET tumor extending into the internal capsule, corpus callosum or brainstem. (multiple choices allowed)",
                     "minCardinality": "1",
                     "maxCardinality": "3",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.158474128294561234684698963176949745267",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID28454",
                           "codeMeaning": "none",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        },
                        {
                           "codeValue": "RID6915",
                           "codeMeaning": "corpus callosum",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6941",
                           "codeMeaning": "internal capsule",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        },
                        {
                           "codeValue": "RID6677",
                           "codeMeaning": "brainstem",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  },
                  {
                     "label": "F25 - Calvarial remodeling",
                     "itemNumber": "25",
                     "authors": "Justin Kirby",
                     "explanatoryText": "Calvarial remodeling is defined as visible erosion/remodeling of inner table of skull (possibly a secondary sign of slow growth).",
                     "minCardinality": "1",
                     "maxCardinality": "1",
                     "shouldDisplay": "true",
                     "groupLabel": "",
                     "id": "2.25.232585054265451406016857784730316000640",
                     "annotatorConfidence": "false",
                     "AllowedTerm": [
                        {
                           "codeValue": "RID28473",
                           "codeMeaning": "absent",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0",
                           "defaultAnswer": "true"
                        },
                        {
                           "codeValue": "RID28472",
                           "codeMeaning": "present",
                           "codingSchemeDesignator": "RadLex",
                           "codingSchemeVersion": "1.0"
                        }
                     ]
                  }
               ]
            },
            "AllowedTerm": {
               "codeValue": "RID4026",
               "codeMeaning": "glioma",
               "codingSchemeDesignator": "RadLex",
               "codingSchemeVersion": "1.0",
               "defaultAnswer": "true"
            }
         },
         {
            "label": "Lesion Size (measure using the Normals tool)",
            "itemNumber": "1",
            "authors": "Default User",
            "explanatoryText": "Lesion size is defined as the largest perpendicular (x-y) cross- sectional diameter of entire T2 or FLAIR signal abnormality (longest dimension x perpendicular dimension) measured the single axial image that reveals the largest cross-sectional area of the lesion.  If possible, normal structures should be excluded.",
            "minCardinality": "1",
            "maxCardinality": "1",
            "shouldDisplay": "true",
            "groupLabel": "",
            "id": "2.25.64789457130859259574713435581518899790",
            "GeometricShape": "MultiPoint"
         },
         {
            "label": "Lesion Size (measure using the Normals tool)",
            "itemNumber": "2",
            "authors": "Default User",
            "explanatoryText": "Lesion size is defined as the largest perpendicular (x-y) cross- sectional diameter of entire T2 or FLAIR signal abnormality (longest dimension x perpendicular dimension) measured the single axial image that reveals the largest cross-sectional area of the lesion.  If possible, normal structures should be excluded.",
            "minCardinality": "1",
            "maxCardinality": "1",
            "shouldDisplay": "false",
            "groupLabel": "",
            "id": "2.25.220490962946921260789645988124320688569",
            "GeometricShape": "MultiPoint"
         }
      ]
   }
}

